Key Takeaways
- Revenue growth accelerates, U.S. crosses milestone: Constant-currency revenue grew 13.5% YoY and 4.4% QoQ, with the U.S. business crossing a $100 million run rate for the first time on 5% organic QoQ growth.
- Margins dip on wage hikes and acquisition dilution: EBITDA margin fell 140 bps QoQ to 16.1%, driven by wage increases (130-140 bps impact) and a 30-40 bps drag from the lower-margin BizAnalytica acquisition.
- U.K. order book strengthens, but near-term growth waits: U.K. order booking improved significantly, positioning the region for Q4 growth, though Q3 faces seasonal furlough headwinds and decision delays are expected to persist.
- Account mining and acquisition synergies begin to pay off: The Blue Cross Blue Shield account is tracking toward a $15 million run rate, and joint synergy deals from recent acquisitions are building pipeline across geographies.
- What to watch next quarter: Whether the U.K. order book converts to revenue in Q4 as guided, the pace of margin recovery back toward the 17-19% range, and any early signs that Generative AI proof-of-concepts are scaling into larger enterprise use cases.
Revenue Performance & Regional Dynamics
- U.S. pivot to growth: Organic constant-currency growth of 5% QoQ, excluding BizAnalytica, marks a turning point; healthcare and manufacturing verticals led, while state and local government trailed expectations.
- U.K. order book builds, revenue lags: Order booking improved materially, but revenue conversion faces a Q3 seasonal furlough drag; management expects the strong backlog to drive Q4 growth.
- U.K. technical debt cycle: A published report projects certain government departments will need two cycles of spend, roughly eight years, to work through accumulated technical debt, creating a sustained addressable market.
- Middle East selectivity: Management is getting more careful about business taken in the region, focusing on higher-margin work and larger accounts.
- Europe remains opportunistic: Selective opportunities will be pursued depending on the country, with no broad-based push signaled.
Hiral Chandrana: "We've crossed USD 100 million run rate as a combined U.S. business for the first time in Mastek after many years. And so we believe from here on, there should be more positive momentum."
Margin Walk & Recovery Path
- Q2 margin bridge: Wage hikes implemented in August took 130-140 bps for two months; BizAnalytica integration added 30-40 bps of dilution; operating levers including subcontractor conversion and pyramid management provided a partial offset.
- Utilization improved: Utilization rose QoQ to 82.5%, or 84.1% excluding leaves, driven by subcontractor-to-employee conversion and better pyramid management.
- U.S. margin trajectory: The first target is double-digit margins in the geography, then closer to the company average; management is comfortable with a 2-3% delta given faster growth, aiming for company average in steady state over the next two to three quarters.
- Subcontractor cost structure: Higher than competition due to U.K. public sector onshore requirements; converting subcontractors to employees is a stated margin lever. [15-16]
- Cash flow strengthened: DSOs came down and gross cash rose to INR 312 crores from INR 220 crores in the prior quarter.
Arun Agarwal: "Let us get into 17% to 19% range first, Mohit, and definitely, our endeavor will be to further up it and keep it more closer to 19%. But let us first come back to that range."
Marquee Wins & Account Mining
- U.K. "One Login" program: Won with the Cabinet Office, this program serves as the front door for over 300 government accounts and services, supporting multiple millions of users; announced October 18, 2023.
- U.K. government expansion: Expanding beyond existing presence in borders, immigration, customs, defense, and higher education into new departments including Environment/Food & Rural Affairs, Cabinet Office, and police protection, with a two-to-three-year game plan.
- Healthcare account mining: The Blue Cross Blue Shield account is progressing from a $10 million+ target to a likely $15 million run rate for FY24.
- New framework access: Entered the DSP (digital specialist framework) and a data and analytics framework, widening the addressable public sector surface.
- Oracle Cloud deal in Middle East: Won a healthcare platform company deal to implement Oracle Cloud for business decision-making and financial planning.
- U.S. data cloud deal: Won a deal with a large investment firm to consolidate all data into the cloud for informed portfolio decisions.
- Inorganic synergies materializing: Acquisitions over the last 12-14 months are starting to pay off in joint synergy deals, account mining, and growth in accounts above $1 million.
BizAnalytica Acquisition
- Integration on track: Two months into the acquisition, revenue is in line with the expected USD 14-15 million annualized run rate; Q3 revenue is expected to be slightly higher with a full three months of contribution.
- Synergy pipeline building: Joint deals and pipeline are being built across U.S. and U.K. geographies.
- Margin dilution temporary: The acquisition currently carries lower margins; management expects a return to double-digit margin by the end of this year and closer to Mastek's margin profile next year.
- Acquisition-related costs: A one-time cost of approximately ₹4 crore was recognized in the quarter; total amortization impact on margins was not quantified.
Demand Environment & Headwinds
- Decision delays persist: General delays in client decision-making are expected to continue for at least the next one or two quarters.
- Election cycle overhang: Both the U.K. and U.S. election years are seen as a near-term weighing factor for the next three to four quarters.
- NHS recovery bottoming: The NHS business is seen as having bottomed out a couple of quarters back; management is conservative on FY24 growth by design, with no major incremental revenue expected in Q3/Q4, though deal activity may set the stage for a stronger FY25. [12-13]
- Generative AI as wedge: Customers are evaluating how Generative AI will play a role in their future, which management sees as a potential opportunity to upset some larger incumbents, though it is too early to tell.
Hiral Chandrana: "customers are continuing to look at cost consolidation as well as now evaluating how Generative AI is going to play a role in their future. So we see that as a potential opportunity for us to look at, maybe even looking at upsetting some of the incumbents, some of the larger incumbents. But that's too early to tell."
People & Attrition
- Wage hikes completed: Salary increments were implemented in the quarter even as some peers deferred, reflecting a decision to reward employees who contributed to growth.
- Attrition structurally higher: The business mix is heavily weighted toward digital engineering, cloud transformation, and complex programs requiring niche, specialized skills in high demand; attrition is expected to remain structurally above market but gradually reduce.
- Leadership additions: A new CHRO joined, completing the leadership team; a new healthcare account leader was hired for the U.K.
- Evosys buyout: The last tranche of CCPS buyout for Evosys is expected to occur between December and January (Q3-Q4).
Hiral Chandrana: "the skills are definitely much more niche as well as specialized in some cases. So that is clearly talent that is much more in demand. And that's one of the reasons why we want to make sure we do the right thing for our employees who have contributed to the growth and make sure that they are rewarded."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | Return to 17% to 19% range through operating levers (grade mix, pyramid, subcontractor conversion, utilization) | Coming quarters |
| U.K. revenue growth | Growth driven by strong order booking and deal momentum | Q4 FY24 |
| U.S. margin target | First reach double-digit margin in geography, then closer to company average with 2-3% delta acceptable | Steady state in 2-3 quarters |
| BizAnalytica margin | Return to double-digit margin | End of this year |
| BizAnalytica margin | Closer to Mastek margin profile | Next year |
| Decision delays | General delays in client decisions will persist | At least next 1-2 quarters |
| NHS revenue | No major incremental growth; deals and order book may set stage for stronger FY25 | Q3/Q4 FY24 |
| U.K. government expansion | Expand purview into new departments (Environment/Food & Rural Affairs, Cabinet Office, police protection) | Next 2-3 years |
| U.S. healthcare vertical | Reach USD 100 million vertical size | Next 3-4 years |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹766 cr, +5.6% QoQ and +22.4% YoY |
| Constant currency revenue growth | +4.4% QoQ, +13.5% YoY |
| US dollar revenue growth | +18.6% YoY |
| Organic revenue growth (INR) | +2.7% QoQ, excluding BizAnalytica |
| US business organic growth (constant currency) | +5% QoQ, excluding BizAnalytica |
| Operating EBITDA margin | 16.1%, down 140 bps QoQ; wage hikes impact of 130–140 bps and BizAnalytica dilution of 30–40 bps |
| PAT | ₹65.3 cr, vs ₹73.5 cr in Q1 FY24 |
| 12-month order backlog growth (INR) | +5.6% QoQ, +22.3% YoY |
| 12-month order backlog growth (constant currency) | +13.4% YoY |
| Headcount | 5,598, marginal increase QoQ including BizAnalytica colleagues |
| Utilization | 82.5%, excluding leaves 84.1% |
| Gross cash | ₹312 cr, vs ₹220 cr in Q1 FY24 |
| Borrowings | ₹477 cr as of 30 September |
| Clients added | 29 during the quarter |
| US business run rate | Crossed $100 million for the first time |